PERSONAL INFORMATION
Name: WANG Yingying
Gender: Female
Title: Associate professor/ supervisor
CONTACT INFORMATION
Email: yingyingvictoria@hotmail.com
Address: Department of Immunology, School of Basic Medicine, Chongqing Medical university
Phone: +86-15623696683
EDUCATION EXPERIENCE
2011-2014 PhD in life science in Lorrain university in France
2010-2011 Master Degree in Tissue regeneration and cell therapy in Lorrain university in France
2002-2009 Seven-year program of clinical medicine in Wuhan university
WORKING EXPERIENCE
2021.09- Associate professor in department of Immunology, School of Basic Medicine, Chongqing Medical University
2014.12-2021.08 Attending doctor in department of hematology in Zhongnan hospital of Wuhan university
2013.11-2014.10 Interne in department of hematology in CHR (Regional hospital of Mercy in Metz) in Lorrain，France
2009-2010 Interne in department of hematology in Zhongnan hospital of Wuhan university
RESEARCH INTERESTS
1. Preclinical research about virus specific T cell (CMV-VST,EBV-VST) and its clinical applications.
2. Chronic inflammation and myeloproliferative disease (MPN), especially monocyte implicated in MPN.
3. Chronic virus infection and trained immunity.
PUBLICATIONS
1. YingyingWang, XuelanZuo. Cytokines frequently implicated in myeloproliferative neoplasms
Cytokine X. 2019; doi.org/10.1016/j.cytox.2019.100005
2. Qian C#, Wang YY#,Cai H, Laroye C, De Carvalho Bittencourt M, Clement L, Stoltz JF, Decot V, Reppel L, Bensoussan D*. Adenovirus-specific T-cell Subsets in Human Peripheral Blood and After IFN-γ Immunomagnetic Selection. J Immunother. 2016;39(1):27-35
3. Wang YY, Aissi-Rothe L, Virion JM, De Carvalho BM, Ulas N, Audonnet S, Salmon A, Laurence C, Venard V, Jeulin H, Bensoussan D*. Combination of Epstein-Barr virus nuclear antigen 1,3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy, Cytotherapy, 2014,16(1):122-134
4. Aïssi-Rothé L#, Wang YY#, Decot V, Stoltz JF, Bensoussan D*. Immunothérapie adoptive anti- virale après allogreffe de cellules souches hématopoïétiques, Virologie, 2012, 16(6): 345-355
5. Qian, Chongsheng(#) ; Campidelli, Arnaud(#); Wang, Yingying; Cai, Huili; Venard, Veronique; Jeulin, Helene; Dalle, Jean Hugues; Pochon, Cecile; D'aveni, Maud; Bruno, Benedicte; Paillard, Catherine; Vigouroux, Stephane; Jubert, Charlotte; Ceballos, Patrice; Marie-Cardine, Aude; Galambrun, Claire; Cholle, Clement; Clerc Urmes, Isabelle; Petitpain, Nadine; De Carvalho Bittencourt, Marcelo; Decot, Veronique; Reppel, Loic; Salmon, Alexandra; Clement, Laurence; Bensoussan, Daniele* , Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial. J Hematol Oncol. 2017;10(1):102.
6. Qian C(#), Wang Y, Reppel L, D’aveni M, Campidelli A, Decot V, Bensoussan D(*).Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT. Bone Marrow Transplant. Bone Marrow Transplantation, 2017;53(2): 114~122
7. Aissi-Rothé L, Decot V, Wang YY, Stoltz JF, Bensoussan D*. Apport des méthodes d’isolement immunomagnétique de lymphocytes T cytotoxiques dans la restauration rapide d’une immunité antivirale après allogreffe de cellules souches hématopoïétiques, Revue Francophone des Laboratoires,2012,439(2):55-60
8. Wang Y, Li J, Liu L, Li J, Liu X, He J, Wang C, Ye D, Wang X, Zhou F. Measures for preventing nosocomial infection with SARS-CoV-2 in hematology departments. Ann Hematol. 2020 Aug;99(8):1933-1938. doi: 10.1007/s00277-020-04127-x. Epub 2020 Jun 29. PMID: 32601797; PMCID: PMC7323882.
